Open access · CC-BY
via OpenAlex
Impaired dopamine metabolism in Parkinson’s disease pathogenesis
Anna Masato, Nicoletta Plotegher, Daniela Boassa, Luigi Bubacco
Molecular Neurodegeneration · 2019 · ▲ 324 citations
Abstract
A full understanding of Parkinson's Disease etiopathogenesis and of the causes of the preferential vulnerability of nigrostriatal dopaminergic neurons is still an unsolved puzzle. A multiple-hit hypothesis has been proposed, which may explain the convergence of familial, environmental and idiopathic forms of the disease. Among the various determinants of the degeneration of the neurons in Substantia Nigra pars compacta, in this review we will focus on the endotoxicity associated to dopamine dyshomeostasis. In particular, we will discuss the relevance of the reactive dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL) in the catechol-induced neurotoxicity. Indeed, the synergy between the catechol and the aldehyde moieties of DOPAL exacerbates its reactivity, resulting in modification of functional protein residues, protein aggregation, oxidative stress and cell death. Interestingly, αSynuclein, whose altered proteostasis(definition) is a recurrent element in Parkinson's Disease pathology, is considered a preferential target of DOPAL modification. DOPAL triggers αSynuclein oligomerization leading to synapse physiology impairment. Several factors can be responsible for DOPAL accumulation at the pre-synaptic terminals, i.e. dopamine leakage from synaptic vesicles, increased rate of dopamine conversion to DOPAL by upregulated monoamine oxidase and decreased DOPAL degradation by aldehyde dehydrogenases. Various studies report the decreased expression and activity of aldehyde dehydrogenases in parkinsonian brains, as well as genetic variants associated to increased risk in developing the pathology. Thus, we discuss how the deregulation of these enzymes might be considered a contributing element in the pathogenesis of Parkinson's Disease or a down-stream effect. Finally, we propose that a better understanding of the impaired dopamine metabolism in Parkinson's Disease would allow a more refined patients stratification and the design of more targeted and successful therapeutic strategies.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1186/s13024-019-0332-6
- Canonical
- link ↗
- Fetched
- 2026-06-03 MST
Cite this
APA
Masato, A., Plotegher, N., Boassa, D., & Bubacco, L. (2019). Impaired dopamine metabolism in Parkinson’s disease pathogenesis. <em>Molecular Neurodegeneration</em>. https://doi.org/10.1186/s13024-019-0332-6
Vancouver
Masato A, Plotegher N, Boassa D, Bubacco L. Impaired dopamine metabolism in Parkinson’s disease pathogenesis. Molecular Neurodegeneration. 2019. doi:10.1186/s13024-019-0332-6.
BibTeX
@article{anna2019Impair,
title = {Impaired dopamine metabolism in Parkinson’s disease pathogenesis},
author = {Anna Masato and Nicoletta Plotegher and Daniela Boassa and Luigi Bubacco},
journal = {Molecular Neurodegeneration},
year = {2019},
doi = {10.1186/s13024-019-0332-6},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Neurobiology of Aging 2007
Preprint · OA
Synuclein activates microglia in a model of Parkinson's disease
Journal of Physical Activity and Health 2013
Citation only
The Associations Between Cardiovascular Risk Factors, Physical Activity, and Arterial Stiffness in Youth
Ageing Research Reviews 2014
Open access · CC-BY
Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?
npj Parkinson s Disease 2023
Open access · CC-BY
DOPAL initiates αSynuclein-dependent impaired proteostasis and degeneration of neuronal projections in Parkinson’s disease
Purdue e-Pubs (Purdue University System) 2010
Preprint
Role of alpha-synuclein primary structure and oxidative stress in Parkinson's disease pathology
Nature Reviews Molecular Cell Biology 2023
Preprint · OA